Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study
about
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trialThe ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir
P2860
Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pharmacologic boosting of ataz ...... ropensity-score adjusted study
@ast
Pharmacologic boosting of ataz ...... ropensity-score adjusted study
@en
Pharmacologic boosting of ataz ...... ropensity-score adjusted study
@nl
type
label
Pharmacologic boosting of ataz ...... ropensity-score adjusted study
@ast
Pharmacologic boosting of ataz ...... ropensity-score adjusted study
@en
Pharmacologic boosting of ataz ...... ropensity-score adjusted study
@nl
prefLabel
Pharmacologic boosting of ataz ...... ropensity-score adjusted study
@ast
Pharmacologic boosting of ataz ...... ropensity-score adjusted study
@en
Pharmacologic boosting of ataz ...... ropensity-score adjusted study
@nl
P2093
P2860
P50
P1433
P1476
Pharmacologic boosting of ataz ...... ropensity-score adjusted study
@en
P2093
David Plainchamp
Eric Legac
Françoise Borsa-Lebas
Gwenaël Le Moal
Laurent Hocqueloux
Philippe Choisy
Thierry Prazuck
Xavier de la Tribonnière
Yazdan Yazdanpanah
P2860
P304
P356
10.1371/JOURNAL.PONE.0049289
P407
P577
2012-11-09T00:00:00Z